Population Pharmacokinetics of Intravenous Polymyxin B in Critically Ill Patients: Implications for Selection of Dosage Regimens-Reference-Cited by-同舟云学术

Population Pharmacokinetics of Intravenous Polymyxin B in Critically Ill Patients: Implications for Selection of Dosage Regimens

Published:2013-05-22 Issue:4 Volume:57 Page:524-531
ISSN:1537-6591
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:

Author:

Sandri Ana M.,Landersdorfer Cornelia B.,Jacob Jovan,Boniatti Márcio M.,Dalarosa Micheline G.,Falci Diego R.,Behle Tainá F.,Bordinhão Rosaura C.,Wang Jiping,Forrest Alan,Nation Roger L.,Li Jian,Zavascki Alexandre P.

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Link

http://academic.oup.com/cid/article-pdf/57/4/524/17854181/cit334.pdf

Reference25 articles.

1. Colistin: the re-emerging antibiotic for multidrug-resistant gram-negative bacterial infections;Li;Lancet Infect Dis,2006

2. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review;Zavascki;J Antimicrob Chemother,2007

3. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections;Falagas;Clin Infect Dis,2005

4. Polymyxins revisited;Landman;Clin Microbiol Rev,2008

5. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa;Bergen;Antimicrob Agents Chemother,2006

Cited by 351 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PBP-3 directed therapy in VIM-producing Pseudomonas aeruginosa creates bacterial transformers, persisters in disguise;International Journal of Antimicrobial Agents;2024-09

2. Pharmacokinetics and safety of colistin sulfate after single and multiple intravenous doses in healthy Chinese subjects;International Journal of Antimicrobial Agents;2024-09

3. A simple HPLC–MS/MS method for the determination of polymyxin B in human plasma and its application in the pharmacokinetic study in elderly patients infected with multidrug-resistant Gram-negative bacteria;Frontiers in Pharmacology;2024-08-16

4. Three methods to optimise polymyxin B dosing using estimated AUC after first dose: validation with the data generated by Monte Carlo simulation;Xenobiotica;2024-07-08

5. Efficacy and Safety Factors Related to Plasma Concentration-Optimized Polymyxin B Therapy in Treating Carbapenem-Resistant Gram-Negative Bacterial Infections in China;Infection and Drug Resistance;2024-07